在怀孕期间,在患有乙型肝炎的母亲身上进行诺福维尔阿拉芬胺治疗
Xingfei Pan1, Liyang Zhou1, Jing Hu2
1Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Alimentary pharmacology & therapeutics
|May 3, 2025
概括
诺福维尔阿拉芬胺 (TAF) 对于患有慢性乙型肝炎的孕妇来说是一种安全的抗病毒选择,与不治疗相比,对婴儿没有增加的风险. 这一发现支持TAF作为怀孕期间可行的治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 怀孕期间的慢性乙型肝炎需要在患有晚期纤维化症的母亲接受抗病毒治疗.
- 目前的指导方针有利于特诺福维尔二氧化硫 fumarate (TDF),但它对脏和骨健康构成风险.
- 对于有TDF相关不良影响风险的孕妇,需要使用替代抗病毒药物.
研究的目的:
- 为了评估在怀孕期间治疗慢性乙型肝炎时的特诺福维尔阿拉芬胺 (TAF) 治疗的安全性和有效性.
- 为了比较TAF治疗的母亲与没有抗病毒治疗的母亲的怀孕结果和婴儿健康状况.
- 在接受TAF的患有慢性乙型肝炎的孕妇中确定不良事件的预测因素.
主要方法:
- 对患有慢性乙型肝炎的母亲接受TAF治疗或不接受治疗的回顾性研究.
- 分类为三组:TAF-第一季度,TAF-末季度,没有治疗.
- 倾向性得分匹配以确保组别可比性;严重不良事件和垂直传播率的评估.
主要成果:
- 在TAF组和不接受治疗组之间,胎儿损失,低出生体重,早产或先天异常没有显著差异.
- 孕期糖尿病在TAF-第一季度组中发生的频率更高.
- 体外受精是严重不良事件的唯一预测因素;在产后28周没有报告B型肝炎病毒的婴儿传播.
结论:
- 在整个怀孕期间,诺福维尔阿拉芬胺 (TAF) 治疗对于患有慢性乙型肝炎的母亲及其婴儿是安全的.
- 对于患有慢性乙型肝炎的孕妇来说,TAF治疗是一种可行的,安全的TDF替代方案.
- 这项研究支持TAF用于怀孕期间治疗慢性乙型肝炎.
更多相关视频
相关概念视频
01:07Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
01:10Retrovirus Life Cycles
45.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
991
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
991